Intismeran & Neoantigen Cancer Vaccine Simulator

1. Genomic & Vaccine Setup PRESETS

Clinical Tumor Scenario

Tumor Mutational Burden (TMB) 34.2 mut/Mb

mRNA Vaccine Neoantigens 20 peptides

HLA IC50 Stringency ≤ 500 nM

mRNA-LNP Dose 100 μg

Adjuvant Anti-PD-1 Checkpoint

B2M / HLA Intactness (No Escape)

Mechanism: Intismeran encapsulates synthetic mRNA encoding patient-specific mutated neoepitopes into lipid nanoparticles (LNPs), triggering clonal CD8+ T-cell expansion against tumor subclones.

Dendritic Cell: LNP → HLA-I Presentation T-Cell Lysis Rate: 84% Tumor Microenvironment

2. Tumor Burden & CTL Trajectory (180-Day ODE Model) COMPLETE REMISSION

3. Clinical Telemetry & HLA Matrix

Predicted 1-Yr PFS

78.4%

CTL Expansion Factor

48.2x

Strong HLA Binders

14 / 20

Immune Escape Risk

6.2%

High-Ranked Somatic Neoepitopes (NetMHC IC50)

Gene & Mutation	HLA Allele	IC50 (nM)	Affinity

Bioinformatic Synthesis

High TMB generates ample subclonal neoepitopes. Strong HLA-A*02:01 presentation coupled with anti-PD-1 overcomes T-cell exhaustion.